In April 2025, the French authorities issued, a public health order suspending the importation, marketing, sale, and distribution of dietary supplements containing Garcinia Cambogia Desr. and any preparation thereof for a period of one year, from the 17th of April 2025, to the 17th of April 2026. This came after health risk concerns were raised by the French Agency for Food, Environmental, and Occupational Health & Safety (ANSES), which included severe adverse reactions associated with the intake of supplements such as liver injury.
This warning was seen as a result of reports of severe side effects associated with the consumption of supplements containing Garcinia cambogia. Documented cases included cases of acute hepatitis, psychiatric disorders, cardiovascular complications, as well as musculoskeletal disorders. Notably, some cases occurred in otherwise healthy individuals with no pre-existing liver conditions.
Given the severity and unpredictability of these health outcomes, French authorities considered that immediate precautionary action was needed to protect public health. Consequently, this notification involves the withdrawal of all affected products from the market and their recall from consumers. [1]
The French regulatory decision to suspend the use of Garcinia cambogia supplements resulted from a comprehensive risk assessment by ANSES in response to the increased reports of severe adverse effects on health. The key component, hydroxycitric acid (HCA), has been extensively used as a dietary supplement in the management of overweight individuals and as an anti-appetite agent. Severe side effects observed relate to acute hepatitis, which can lead to hospitalization, as well as neuropsychiatric disorders, cardiovascular events, pancreatitis, as well as rhabdomyolysis, the latter in healthy individuals as well as in persons with underlying health conditions.
The evidence suggested that the risks observed were not associated with the brands or the population groups, but rather with the ingredient itself. Given the unresolved safety concerns and the ongoing European Food Safety Authority (EFSA) evaluation of HCA, France implemented a precautionary, one-year national suspension of Garcinia cambogia supplements. [2]
Product description | Brand | Product | Size | Issue | Affected Regions |
Garcinia cambogia supplements (capsule, tablet, powder) standardized for HCA; marketed for weight loss and appetite suppression | Multiple | Garcinia cambogia | Multiple SKUs | Safety risk – acute hepatitis; recall & suspension | France |
The main issue identified by the French government is the risk of serious liver injury and other systemic adverse effects linked to the consumption of Garcinia cambogia supplements.
Reported health concerns include:
Furthermore, some of the individuals displayed no prior medical history that indicated a predisposition to the condition. This heightened the degree of concern regarding the unpredictability of the response.
As dietary supplements were widely available and perceived as safe due to the “natural” positioning of the dietary supplements, it was emphasized that the fact that they were botanically derived is not indicative of their safety. The cases were serious, and removal of the product ensued. [3]
ANSES officially issued a recommendation to consumers not to consume food dietary supplements containing Garcinia cambogia. After this recommendation, the French ministries laid down a suspension order for one year under the national food safety regulation.
The regulatory concerns include:
France has informed the European Commission about this national precautionary measure according to the procedures of EU General Food Law. The suspension is temporary until further scientific conclusions are drawn but is binding throughout the one-year period. [4]
Consumers are strongly advised not to assume safety based solely on herbal or botanical origin. [5]
The suspension of Garcinia cambogia supplements in France demonstrates the changing nature of government regulation related to botanicals ingredients used in food supplements. While plant-based ingredients are often marketed as natural alternatives, safety evaluation must meet rigorous toxicological and clinical standards.
This regulatory action underscores several critical industry lessons:
For manufacturing companies operating in the global market, review of toxicological information, clinical safety documentation, and regulatory compliance assessment are essential. There is a need to enhance traceability of food ingredients, extract standardization, and systems monitoring adverse results to avoid such regulatory disruptions.
The case also illustrates how rapidly regulatory positions can change when new safety evidence emerges.
One-year suspension and recall of Garcinia cambogia supplementation in France underlined severe health hazards such as acute hepatitis, convincing the need for a close safety overview regarding botanical raw materials. The manufacturers should monitor regulatory updates very closely and ensure timely compliance with evolving standards.
Partner with Food Research Lab for expert safety assessment, regulatory guidance, and scientific support in developing compliant, market-ready dietary supplements.
Food Research Lab strives for excellence in new Food, Beverage and Nutraceutical Product Research and Development by offering cutting edge scientific analysis and expertise.
